Open AccessA protocol for DUAL pathway inhibition (low-dose rivaroxaban and aspirin) as compared to aspirin only to improve endothelial function in peripheral artery disease
Author(s) -
LH Willems,
Dhj Thijssen,
A. Rogier T. Donders,
RJ. van der Vijver-Coppen,
LA Groh,
M.M.P.J. Reijnen,
MC Warlé
Publication year - 2021
Publication title -
medicine, case reports and study protocols
Language(s) - English
Resource type - Journals
ISSN - 2691-3895
DOI - 10.1097/md9.0000000000000163
Subject(s) - medicine , rivaroxaban , adverse effect , aspirin , endothelial dysfunction , cardiology , clinical endpoint , claudication , cilostazol , clinical trial , anesthesia , vascular disease , arterial disease , warfarin , atrial fibrillation